Crowell & Moring Represents Third Rock Ventures in $108 Million Series C Financing for Terremoto Biosciences
Firm News | less than 1 min read | 04.15.26
Boston and San Francisco – April 15, 2026: Crowell & Moring represented investor Third Rock Ventures in the closing of a $108 million Series C financing round for Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines.
Along with Third Rock, the financing included support from existing investors OrbiMed, Novo Holdings, and Cormorant Asset Management, LP, as well as from new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines. Proceeds from the financing will enable Terremoto to advance its selective AKT1 inhibitor programs through Phase 1 clinical development for patients with cancer and rare diseases such as hereditary hemorrhagic telangiectasia.
The financing transaction was led by partner Kurt Machemer (Boston).
Insights
Firm News | 1 min read | 07.30.26
Crowell & Moring Earns National Recognition in Managing IP’s 2026 USA IP Stars Rankings
Chicago – July 30, 2026: Managing Intellectual Property has recognized nine Crowell & Moring attorneys and five practice areas in its 2026 IP Stars rankings for the United States, underscoring the depth, breadth, and technical strength of the firm’s global Intellectual Property practice, which includes more than 100 attorneys, patent agents and technical advisors. The guide “covers a variety of IP practice areas and more than 80 jurisdictions, making it the most comprehensive and widely respected IP practitioner guide in the legal profession.”
Firm News | 2 min read | 07.29.26
Firm News | 4 min read | 07.22.26
Firm News | 2 min read | 07.21.26
